Swedish Orphan Biovitrum AB (SOBI) AI Stock Analysis

• Market Cap: kr102.44B
• Dividend Yield: N/A
• Average Volume (3M): 342.02K
• Price to Earnings (P/E): 26.0
• Beta (1Y): 0.90
• Revenue Growth: 13.38%
• EPS Growth: 80.71%
• Country: SE
• Employees: 1,895
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.55
• Shares Outstanding: 356,000,060
• 10 Day Avg. Volume: 391,582
• 30 Day Avg. Volume: 342,019
• PEG Ratio: 14.76
• Price to Book (P/B): 2.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 19.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr350.00
• Price Target Upside: 16.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

Swedish Orphan Biovitrum AB scores well due to its strong financial performance, characterized by consistent revenue growth and robust profitability margins. The balanced financial structure and effective cash management further support its stability. However, the technical analysis indicates some caution due to potential overbought conditions, and the valuation suggests the stock may be relatively expensive. These factors combine to give an overall score that reflects a stable but cautiously optimistic outlook.

Swedish Orphan Biovitrum AB Business Overview & Revenue Model

Company Description

Swedish Orphan Biovitrum AB (SOBI) is a Sweden-based biopharmaceutical company that specializes in the development and commercialization of treatments for rare diseases. The company focuses on two key areas: Hematology and Immunology, offering innovative therapies that address unmet medical needs. SOBI is known for its strong portfolio of biologic drugs, which include treatments for hemophilia and other rare conditions. The company operates globally, providing patients with access to specialized medicines and collaborating with healthcare professionals to advance medical science.

How the Company Makes Money

SOBI makes money primarily through the sale of its pharmaceutical products, targeting niche markets in the rare disease sectors of Hematology and Immunology. Its revenue model is centered around the commercialization of biologic drugs, which often have premium pricing due to their specialized nature and the high costs associated with their development. Key revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. SOBI also benefits from collaborations that enhance its research and development efforts, enabling the company to expand its product pipeline and sustain its market presence.

Swedish Orphan Biovitrum AB Financial Statement Overview

Summary

Swedish Orphan Biovitrum AB demonstrates a solid financial performance across income, balance sheet, and cash flow statements. The company shows consistent revenue growth and maintains strong profitability margins, reflecting effective management and operational efficiency. The balance sheet illustrates a healthy capital structure with a sensible debt-to-equity ratio, while cash flow generation remains robust, supporting ongoing operations and future growth. Continuous monitoring of leverage levels and cash conversion efficiency will be essential for sustaining long-term financial stability.

Income Statement

Swedish Orphan Biovitrum AB shows strong financial performance with a consistent increase in revenue from 2020 to TTM (Trailing-Twelve-Months) with a notable revenue growth rate of 4.1% from the previous annual period. The company maintains robust profitability, with a gross profit margin of 74.9% and a net profit margin of 15.1% in TTM. EBIT and EBITDA margins are also healthy at 21.7% and 35.8% respectively, indicating efficient core operations and strong cash generation capabilities. Despite slight fluctuations, the upward trajectory in revenue and profitability margins reflects a well-managed income statement.

Balance Sheet

The balance sheet presents a stable financial position with total assets of 70.1 billion and stockholders' equity of 39 billion in TTM. The debt-to-equity ratio stands at a reasonable 0.36, indicating a balanced approach to leveraging. Return on equity remains strong at 10.1%, showcasing effective utilization of equity to generate profits. The equity ratio of 55.7% suggests a solid capital structure with substantial equity financing. While the company has managed debt effectively, maintaining this balance is crucial to mitigate potential risks associated with high leverage.

Cash Flow

The company's cash flow statement highlights efficient cash management. Operating cash flow to net income ratio is favorable at 1.93, indicating strong cash generation relative to net income. Free cash flow has shown significant growth of 21.5% from the previous year, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow to net income ratio stands at 1.35, suggesting room for improvement in converting earnings to cash. Overall, cash flows are robust, supporting the company's operational and investment activities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
26.24B	26.03B	22.12B	18.79B	15.53B	15.26B
	Gross Profit
19.66B	20.24B	17.13B	14.01B	12.04B	12.04B
	EBIT
5.70B	5.63B	4.07B	3.81B	3.73B	4.82B
	EBITDA
9.41B	9.30B	7.23B	6.05B	5.71B	6.73B
	Net Income Common Stockholders
3.96B	3.88B	2.41B	2.64B	2.68B	3.25B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
997.00M	1.14B	904.00M	1.36B	1.04B	404.00M
	Total Assets
70.12B	75.44B	74.03B	52.50B	48.66B	48.28B
	Total Debt
14.02B	16.73B	20.48B	9.10B	10.91B	14.57B
	Net Debt
13.02B	15.60B	19.58B	7.74B	9.86B	14.17B
	Total Liabilities
31.08B	35.15B	40.16B	25.97B	25.46B	28.08B
	Stockholders Equity
39.03B	40.29B	33.87B	26.52B	23.20B	20.21B
Cash Flow		Free Cash Flow
5.33B	4.38B	-473.00M	3.19B	5.10B	1.36B
	Operating Cash Flow
7.62B	7.39B	4.47B	4.67B	5.47B	5.21B
	Investing Cash Flow
-2.44B	-3.09B	-21.90B	-1.48B	-367.00M	-3.96B
	Financing Cash Flow
-4.63B	-4.00B	17.01B	-2.99B	-4.47B	-1.57B

Swedish Orphan Biovitrum AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 299.80
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Positive. The current price of 299.8 is above the 20-day moving average (MA) of 277.78, above the 50-day MA of 286.45, and below the 200-day MA of 306.77, indicating a neutral trend. The MACD of 5.00 indicates Negative momentum. The RSI at 63.59 is Neutral, neither overbought nor oversold. The STOCH value of 77.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SOBI.

Swedish Orphan Biovitrum AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOBI	76 Outperform	kr102.44B	25.97	10.57%	―	13.38%	80.71%
ALIF.B	69 Neutral	kr22.96B	74.26	5.83%	0.24%	6.33%	291.12%
CAMX	68 Neutral	$39.13B	90.43	18.16%	―	8.78%	-5.57%
BONEX	68 Neutral	kr19.02B	155.32	18.01%	―	52.17%	-54.60%
MCOV.B	66 Neutral	kr36.11B	103.42		0.68%	18.16%	35.85%
EKTA.B	64 Neutral	kr19.09B	18.39	9.87%	4.79%	-1.85%	-27.56%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%

Swedish Orphan Biovitrum AB Corporate Events

Sobi AGM Approves Key Resolutions and Growth Initiatives

At the Annual General Meeting held on May 8, 2025, Swedish Orphan Biovitrum AB (Sobi) shareholders approved several key resolutions. These included the adoption of financial statements, re-election of board members, and the implementation of long-term incentive programs. The AGM also authorized the board to issue new shares and convertible bonds, enhancing Sobi’s capacity for future growth and strategic initiatives.